



14th May, 2026

Corporate Relationship Department
M/s. BSE Limited
Mumbai 400001

The Manager - Listing
M/s. National Stock Exchange of India Ltd
Bandra (E) Mumbai 400051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir/Madam,

Sub:- Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above cited subject, we would like to inform you that the Company has received a Demand notice dated 12th May, 2026 from National Pharmaceutical Pricing Authority. The details as required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with read with SEBI's Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 last updated on January 30, 2026 are as under:

S. No.	Particulars	Information
1.	Name of the Authority	National Pharmaceutical Pricing Authority, New Delhi
2.	Nature and details of the action(s) taken or order(s) passed	Demand Notice issued under para 15 of Drugs Price Control Order, 2013 ("DPCO"), directing the Company to deposit an amount of ₹ 4,92,25,923/- (which includes overcharge amount, penalty and interest)
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	Demand notice received on 12 th May, 2026
4.	Details of the violation(s)/contravention(s) committed or alleged to be committed	Demand notice alleges overcharging for 2 drugs covering period between April-2023 to November-2023
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	There is no material impact on financial, operational and other activities of the Company

This is for your information and records.

Thanking you,

Yours faithfully,
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer